

Mismatch Repair Deficiency, Microsatellite Instability, d

JAMA Oncology

3, 1197

DOI: [10.1001/jamaoncol.2016.6762](https://doi.org/10.1001/jamaoncol.2016.6762)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Clinical Development of PD-1/PD-L1 Immunotherapy for Gastrointestinal Cancers: Facts and Hopes. <i>Clinical Cancer Research</i> , 2017, 23, 6002-6011.	3.2	26
2	Clinical relevance of molecular diagnostics in gastrointestinal (GI) cancer: European Society of Digestive Oncology (ESDO) expert discussion and recommendations from the 17th European Society for Medical Oncology (ESMO)/World Congress on Gastrointestinal Cancer, Barcelona. <i>European Journal of Cancer</i> , 2017, 86, 305-317.	1.3	22
3	<i>Helicobacter pylori</i> , gastric cancer and other gastrointestinal malignancies. <i>Helicobacter</i> , 2017, 22, e12413.	1.6	48
4	Epigenetic silencing of MLH1 in endometrial cancers is associated with larger tumor volume, increased rate of lymph node positivity and reduced recurrence-free survival. <i>Gynecologic Oncology</i> , 2017, 146, 588-595.	0.6	77
5	Prognostic significance of Daxx NCR (Nuclear/Cytoplasmic Ratio) in gastric cancer. <i>Cancer Medicine</i> , 2017, 6, 2063-2075.	1.3	21
6	Prognostic and Predictive Value of p21-activated Kinase 6 Associated Support Vector Machine Classifier in Gastric Cancer Treated by 5-fluorouracil/Oxaliplatin Chemotherapy. <i>EBioMedicine</i> , 2017, 22, 78-88.	2.7	37
7	Genomic Profiling to Expand Management Options for Locally Advanced Esophagogastric Cancers: A Proof of Principle Case. <i>JCO Precision Oncology</i> , 2017, 1, 1-6.	1.5	1
8	Perioperative Therapy of Oesophagogastric Adenocarcinoma: Mainstay and Future Directions. <i>Gastroenterology Research and Practice</i> , 2017, 2017, 1-6.	0.7	9
9	Should cT2 esophageal cancer get neoadjuvant treatment before surgery?. <i>Journal of Thoracic Disease</i> , 2017, 9, 2819-2823.	0.6	6
10	Programmed death ligand 1 expression in gastric cancer: correlation with mismatch repair deficiency and HER2-negative status. <i>Cancer Medicine</i> , 2018, 7, 2612-2620.	1.3	49
11	DNA mismatch repair in cancer. , 2018, 189, 45-62.		356
12	Histopathological regression predicts treatment outcome in locally advanced esophagogastric adenocarcinoma. <i>European Journal of Cancer</i> , 2018, 90, 26-33.	1.3	17
13	Genomic Analyses and Precision Oncology in Gastroesophageal Cancer: Forwards or Backwards?. <i>Cancer Discovery</i> , 2018, 8, 14-16.	7.7	10
14	The Role of Microsatellite Instability in Positive Margin Gastric Cancer Patients. <i>Surgical Innovation</i> , 2018, 25, 99-104.	0.4	14
15	Chemoradiotherapy versus chemotherapy as adjuvant treatment for localized gastric cancer: a propensity score-matched analysis. <i>BMC Cancer</i> , 2018, 18, 378.	1.1	5
17	Epstein-Barr virus and mismatch repair deficiency status differ between oesophageal and gastric cancer: A large multi-centre study. <i>European Journal of Cancer</i> , 2018, 94, 104-114.	1.3	50
18	Synchronous metastatic gastric cancer-molecular background and clinical implications with special attention to mismatch repair deficiency. <i>European Journal of Surgical Oncology</i> , 2018, 44, 626-631.	0.5	16
19	Predictive biomarkers for the treatment of resectable esophageal and esophago-gastric junction adenocarcinoma: from hypothesis generation to clinical validation. <i>Expert Review of Molecular Diagnostics</i> , 2018, 18, 357-370.	1.5	6

#	ARTICLE	IF	CITATIONS
20	Upper gastrointestinal malignancies in 2017: current perspectives and future approaches. <i>Future Oncology</i> , 2018, 14, 947-962.	1.1	9
21	Pembrolizumab for treatment of advanced gastric and gastroesophageal junction adenocarcinoma. <i>Future Oncology</i> , 2018, 14, 417-430.	1.1	55
22	Clinical features and survival of gastric cancer patients with DNA mismatch repair deficiency. <i>Journal of Surgical Oncology</i> , 2018, 117, 707-709.	0.8	1
23	Genetic Predictors of Response to Systemic Therapy in Esophagogastric Cancer. <i>Cancer Discovery</i> , 2018, 8, 49-58.	7.7	275
24	Moving Away From a One-Size-Fits-All Approach to Gastric Cancer. <i>Journal of Oncology Practice</i> , 2018, 14, 225-226.	2.5	1
25	Is There a Precise Adjuvant Therapy for Esophagogastric Carcinoma?. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2018, 38, 280-291.	1.8	4
26	The direction of travel to better outcomes for patients with oesophago-gastric cancer. <i>Journal of Thoracic Disease</i> , 2018, 10, 1236-1238.	0.6	0
27	Towards risk-adapted perioperative treatment of gastroesophageal cancer. <i>Annals of Oncology</i> , 2018, 29, 2282-2284.	0.6	0
28	Chemotherapy and novel targeted therapies for operable esophageal and gastroesophageal junctional cancer. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2018, 36-37, 45-52.	1.0	13
29	Distinct molecular subtypes of gastric cancer: from LaurÃ©n to molecular pathology. <i>Oncotarget</i> , 2018, 9, 19427-19442.	0.8	73
30	Refining the management of resectable esophagogastric cancer: FLOT4, CRITICS, OE05, MAGIC-B and the promise of molecular classification. <i>Journal of Gastrointestinal Oncology</i> , 2018, 9, 560-572.	0.6	9
31	Advances in the treatment of gastric cancer. <i>Current Opinion in Gastroenterology</i> , 2018, 34, 465-468.	1.0	74
32	Meta-analysis of prognostic and predictive factors: Towards individual participant data?. <i>European Journal of Cancer</i> , 2018, 104, 224-226.	1.3	1
33	Biomarkers of gastric cancer: Current topics and future perspective. <i>World Journal of Gastroenterology</i> , 2018, 24, 2818-2832.	1.4	300
34	The Thomsen-Friedenreich Antigen: A Highly Sensitive and Specific Predictor of Microsatellite Instability in Gastric Cancer. <i>Journal of Clinical Medicine</i> , 2018, 7, 256.	1.0	14
35	Microsatellite instability in gastric cancer: molecular bases, clinical perspectives, and new treatment approaches. <i>Cellular and Molecular Life Sciences</i> , 2018, 75, 4151-4162.	2.4	150
36	Current status of immunotherapy and immune biomarkers in gastro-esophageal cancers. <i>Journal of Gastrointestinal Oncology</i> , 2018, 9, 196-207.	0.6	18
37	Clinical impact of molecular classifications in gastric cancer. <i>Updates in Surgery</i> , 2018, 70, 225-232.	0.9	13

#	ARTICLE	IF	CITATIONS
38	Peri-operative therapy for operable gastroesophageal adenocarcinoma: past, present and future. <i>Annals of Oncology</i> , 2018, 29, 1377-1385.	0.6	13
39	Radiation Therapy in Gastric Cancer. , 2018, , 1-13.		0
40	Multimodal treatment in locally advanced gastric cancer. <i>Updates in Surgery</i> , 2018, 70, 173-179.	0.9	44
41	Modification of the TNM Staging System for Stage II/III Gastric Cancer Based on a Prognostic Single Patient Classifier Algorithm. <i>Journal of Gastric Cancer</i> , 2018, 18, 142.	0.9	12
42	Immuno-oncology in GI tumours: Clinical evidence and emerging trials of PD-1/PD-L1 antagonists. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 130, 13-26.	2.0	34
43	New Development of Biomarkers for Gastrointestinal Cancers: From Neoplastic Cells to Tumor Microenvironment. <i>Biomedicines</i> , 2018, 6, 87.	1.4	8
44	MUC16 Mutations and Prognosis in Gastric Cancer. <i>JAMA Oncology</i> , 2018, 4, 1698.	3.4	4
45	Gastric cancer: French intergroup clinical practice guidelines for diagnosis, treatments and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCO, SFED, SFRO). <i>Digestive and Liver Disease</i> , 2018, 50, 768-779.	0.4	73
46	Checkpoint blockade in esophagogastric cancer. <i>Journal of Surgical Oncology</i> , 2018, 118, 77-85.	0.8	9
47	Locally advanced gastro-oesophageal cancer: Recent therapeutic advances and research directions. <i>Cancer Treatment Reviews</i> , 2018, 69, 90-100.	3.4	21
48	Microsatellite Instability and Programmed Cell Death-Ligand 1 Expression in Stage II/III Gastric Cancer. <i>Annals of Surgery</i> , 2019, 270, 309-316.	2.1	191
50	Molecular alterations and PD-L1 expression in non-ampullary duodenal adenocarcinoma: Associations among clinicopathological, immunophenotypic and molecular features. <i>Scientific Reports</i> , 2019, 9, 10526.	1.6	9
51	Expression Profile of Markers for Targeted Therapy in Gastric Cancer Patients: HER-2, Microsatellite Instability and PD-L1. <i>Molecular Diagnosis and Therapy</i> , 2019, 23, 761-771.	1.6	18
52	TH9, TH17, and TH22 Cell Subsets and Their Main Cytokine Products in the Pathogenesis of Colorectal Cancer. <i>Frontiers in Oncology</i> , 2019, 9, 1002.	1.3	54
53	MSI/MMR-deficient tumor diagnosis: Which standard for screening and for diagnosis? Diagnostic modalities for the colon and other sites: Differences between tumors. <i>Bulletin Du Cancer</i> , 2019, 106, 119-128.	0.6	61
55	Optimizing adjuvant therapies for the treatment of gastric cancer: with a special focus on Asia. <i>Expert Review of Anticancer Therapy</i> , 2019, 19, 939-945.	1.1	6
56	Gastric cancer: Translating novel concepts into clinical practice. <i>Cancer Treatment Reviews</i> , 2019, 79, 101889.	3.4	60
57	Assessing molecular subtypes of gastric cancer: microsatellite unstable and Epstein-Barr virus subtypes. Methods for detection and clinical and pathological implications. <i>ESMO Open</i> , 2019, 4, e000470.	2.0	35

#	ARTICLE	IF	CITATIONS
58	Individual Patient Data Meta-Analysis of the Value of Microsatellite Instability As a Biomarker in Gastric Cancer. <i>Journal of Clinical Oncology</i> , 2019, 37, 3392-3400.	0.8	293
59	Clinical and molecular prognostic markers of survival after surgery for gastric cancer: tumor-node-metastasis staging system and beyond. <i>Translational Gastroenterology and Hepatology</i> , 2019, 4, 59-59.	1.5	21
60	Single Patient Classifier Assay, Microsatellite Instability, and Epstein-Barr Virus Status Predict Clinical Outcomes in Stage II/III Gastric Cancer: Results from CLASSIC Trial. <i>Yonsei Medical Journal</i> , 2019, 60, 132.	0.9	31
61	Prognostic implication of molecular subtypes and response to neoadjuvant chemotherapy in 760 gastric carcinomas: role of Epstein-Barr virus infection and high- and low-microsatellite instability. <i>Journal of Pathology: Clinical Research</i> , 2019, 5, 227-239.	1.3	63
62	Off-label use of common predictive biomarkers in gastrointestinal malignancies: a critical appraisal. <i>Diagnostic Pathology</i> , 2019, 14, 62.	0.9	4
63	Multimodality management of locally advanced gastric cancer—the timing and extent of surgery. <i>Translational Gastroenterology and Hepatology</i> , 2019, 4, 42-42.	1.5	14
64	Comparison and applicability of molecular classifications for gastric cancer. <i>Cancer Treatment Reviews</i> , 2019, 77, 29-34.	3.4	65
66	Prognostic Impact of Microsatellite Instability in Asian Gastric Cancer Patients Enrolled in the ARTIST Trial. <i>Oncology</i> , 2019, 97, 38-43.	0.9	26
67	The Chinese Society of Clinical Oncology (CSCO): clinical guidelines for the diagnosis and treatment of gastric cancer. <i>Cancer Communications</i> , 2019, 39, 1-31.	3.7	418
68	Comment on “To Treat, or Not to Treat, That is the Question Biomarker-guided Adjuvant Chemotherapy for Stage II and III Gastric Cancer” <i>Annals of Surgery</i> , 2019, 270, e40-e41.	2.1	6
69	Comment on “Microsatellite Instability as a Predictive Biomarker for Adjuvant Chemotherapy in Gastric Cancer” <i>Annals of Surgery</i> , 2019, 270, e39-e40.	2.1	2
70	Expression of PD-L1 and PD-1 in Chemoradiotherapy-Naïve Esophageal and Gastric Adenocarcinoma: Relationship With Mismatch Repair Status and Survival. <i>Frontiers in Oncology</i> , 2019, 9, 136.	1.3	36
71	Perioperative Treatment in Resectable Gastric Cancer: Current Perspectives and Future Directions. <i>Cancers</i> , 2019, 11, 399.	1.7	46
72	The 4th St. Gallen EORTC Gastrointestinal Cancer Conference: Controversial issues in the multimodal primary treatment of gastric, junctional and oesophageal adenocarcinoma. <i>European Journal of Cancer</i> , 2019, 112, 1-8.	1.3	23
73	Perioperative FLOT: new standard for gastric cancer?. <i>Lancet, The</i> , 2019, 393, 1914-1916.	6.3	11
74	The mismatch repair-dependent DNA damage response: Mechanisms and implications. <i>DNA Repair</i> , 2019, 78, 60-69.	1.3	74
75	Stage II gastric cancer: 1 year of S-1 remains standard of care. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 188-189.	3.7	0
76	Ten Thousand Consecutive Gastrectomies for Gastric Cancer: Perspectives of a Master Surgeon. <i>Yonsei Medical Journal</i> , 2019, 60, 235.	0.9	11

#	ARTICLE	IF	CITATIONS
78	Predictive and prognostic implications of microsatellite instability and mismatch repair deficiency in carcinomas of the gastrointestinal tract, liver, and pancreas. <i>Precision Cancer Medicine</i> , 2019, 2, 36-36.	1.8	1
79	Gastric cancer molecular classification and adjuvant therapy: Is there a different benefit according to the subtype?. <i>Journal of Surgical Oncology</i> , 2019, 121, 804-813.	0.8	25
80	Genomics and Targeted Therapies in Gastroesophageal Adenocarcinoma. <i>Cancer Discovery</i> , 2019, 9, 1656-1672.	7.7	37
81	Acquired CTNNB1 Mutation Drives Immune Checkpoint Inhibitor-Associated Acquired Resistance in a Microsatellite Instability-High Gastroesophageal Adenocarcinoma With Brain Metastases. <i>JCO Precision Oncology</i> , 2019, 3, 1-6.	1.5	3
82	Immune Checkpoint Inhibitors in Gastrointestinal Malignancies. , 2019, , 77-101.		0
83	From Tumor Immunology to Immunotherapy in Gastric and Esophageal Cancer. <i>International Journal of Molecular Sciences</i> , 2019, 20, 13.	1.8	111
84	Integrative molecular analysis of colorectal cancer and gastric cancer: What have we learnt?. <i>Cancer Treatment Reviews</i> , 2019, 73, 31-40.	3.4	15
85	Immune Checkpoint Inhibitors in the Treatment of Gastroesophageal Cancer. <i>Drugs</i> , 2019, 79, 1-10.	4.9	18
87	Oligometastatic gastric cancer: An emerging clinical entity with distinct therapeutic implications. <i>European Journal of Surgical Oncology</i> , 2019, 45, 1479-1482.	0.5	10
88	Predictive value of MLH1 and PD-L1 expression for prognosis and response to preoperative chemotherapy in gastric cancer. <i>Gastric Cancer</i> , 2019, 22, 785-792.	2.7	50
89	Prognostic significance of microsatellite instability in gastric and gastroesophageal junction cancer patients undergoing neoadjuvant chemotherapy. <i>International Journal of Cancer</i> , 2019, 144, 1697-1703.	2.3	51
90	Urgent Surgery for Gastric Adenocarcinoma: A Study of the National Cancer Database. <i>Journal of Surgical Research</i> , 2020, 245, 619-628.	0.8	15
91	Prognostic value of mismatch repair deficiency in patients with advanced gastric cancer, treated by surgery and adjuvant 5-fluorouracil and leucovorin chemoradiotherapy. <i>European Journal of Surgical Oncology</i> , 2020, 46, 189-194.	0.5	10
92	Evaluation of the prognostic impact of pathologic response to preoperative chemotherapy using Mandard's Tumor Regression Grade (TRG) in gastric adenocarcinoma. <i>Digestive and Liver Disease</i> , 2020, 52, 107-114.	0.4	24
93	Molecular profiling in gastroesophageal cancer: clinical routine and future perspective. <i>Memo - Magazine of European Medical Oncology</i> , 2020, 13, 440-444.	0.3	3
94	Association Between the Microsatellite Instability Status and the Efficacy of Postoperative Adjuvant Chemoradiotherapy in Patients With Gastric Cancer. <i>Frontiers in Oncology</i> , 2019, 9, 1452.	1.3	9
95	Gastroesophageal cancer: Navigating the immune and genetic terrain to improve clinical outcomes. <i>Cancer Treatment Reviews</i> , 2020, 84, 101950.	3.4	19
96	Multidisciplinary management of stage II-III gastric and gastro-oesophageal junction cancer. <i>European Journal of Cancer</i> , 2020, 124, 67-76.	1.3	16

#	ARTICLE	IF	CITATIONS
97	Preservation of Epstein-Barr virus status and mismatch repair protein status along the metastatic course of gastric cancer. <i>Histopathology</i> , 2020, 76, 740-747.	1.6	13
98	Universal Screening of Gastrointestinal Malignancies for Mismatch Repair Deficiency at Stanford. <i>JNCI Cancer Spectrum</i> , 2020, 4, pkaa054.	1.4	6
99	Idylla microsatellite instability assay versus mismatch repair immunohistochemistry: a retrospective comparison in gastric adenocarcinoma. <i>Journal of Clinical Pathology</i> , 2020, 74, jclinpath-2020-207033.	1.0	14
100	Biomarkers for Precision Treatment in Gastric Cancer. <i>Visceral Medicine</i> , 2020, 36, 364-372.	0.5	14
101	Advances in the treatment of gastric cancer. <i>Current Opinion in Gastroenterology</i> , 2020, 36, 525-529.	1.0	10
102	Remnant gastric cancer: a neglected group with high potential for immunotherapy. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 3373-3383.	1.2	6
103	Sensitivity and polymorphism of Bethesda panel markers in Chinese population. <i>Bulletin Du Cancer</i> , 2020, 107, 1091-1097.	0.6	0
104	Towards Personalization in the Curative Treatment of Gastric Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 614907.	1.3	10
105	Recent Advancements in Biomarkers and Early Detection of Gastrointestinal Cancers. <i>Diagnostics and Therapeutic Advances in GI Malignancies</i> , 2020, , .	0.2	1
106	Immunohistochemical evaluation of mismatch repair proteins and p53 expression in extrauterine carcinosarcoma/sarcomatoid carcinoma. <i>Wspolczesna Onkologia</i> , 2020, 24, 1-4.	0.7	5
107	Genetics and Epigenetics of Sex Bias: Insights from Human Cancer and Autoimmunity. <i>Trends in Genetics</i> , 2020, 36, 650-663.	2.9	23
108	Immunotherapy for Early Stage Colorectal Cancer: A Glance into the Future. <i>Cancers</i> , 2020, 12, 1990.	1.7	12
110	Better prognosis of gastric cancer patients with high levels of tumor infiltrating lymphocytes is counteracted by PD-1 expression. <i>Oncolimmunology</i> , 2020, 9, 1824632.	2.1	13
111	The metastatic pattern of intestinal and diffuse type gastric carcinoma – A Dutch national cohort study. <i>Cancer Epidemiology</i> , 2020, 69, 101846.	0.8	24
113	Prophylactic chemotherapeutic hyperthermic intraperitoneal perfusion reduces peritoneal metastasis in gastric cancer: a retrospective clinical study. <i>BMC Cancer</i> , 2020, 20, 827.	1.1	8
114	<p>Gastric Signet Ring Cell Carcinoma: Current Management and Future Challenges</p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 7973-7981.	0.9	18
115	Gastric cancer. <i>Lancet, The</i> , 2020, 396, 635-648.	6.3	2,084
116	Current status and future potential of predictive biomarkers for immune checkpoint inhibitors in gastric cancer. <i>ESMO Open</i> , 2020, 5, e000791.	2.0	25

#	ARTICLE	IF	CITATIONS
117	Overview of Epstein-Barr-Virus-Associated Gastric Cancer Correlated with Prognostic Classification and Development of Therapeutic Options. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9400.	1.8	12
118	Mismatch Repair System Genomic Scars in Gastroesophageal Cancers: Biology and Clinical Testing. <i>Gastrointestinal Disorders</i> , 2020, 2, 341-352.	0.4	7
119	Tumor-Associated CD68+, CD163+, and MARCO+ Macrophages as Prognostic Biomarkers in Patients With Treatment-Naïve Gastroesophageal Adenocarcinoma. <i>Frontiers in Oncology</i> , 2020, 10, 534761.	1.3	20
120	From biology to surgery: One step beyond histology for tailored surgical treatments of gastric cancer. <i>Surgical Oncology</i> , 2020, 34, 86-95.	0.8	4
121	Microsatellite Instability-Related ACVR2A Mutations Partially Account for Decreased Lymph Node Metastasis in MSI-H Gastric Cancers. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 3809-3821.	1.0	8
122	Classification of gastric cancer by EBV status combined with molecular profiling predicts patient prognosis. <i>Clinical and Translational Medicine</i> , 2020, 10, 353-362.	1.7	13
123	Gastrointestinal cancers: current biomarkers in esophageal and gastric adenocarcinoma. <i>Translational Gastroenterology and Hepatology</i> , 2020, 5, 55-55.	1.5	29
124	MSI and EBV Positive Gastric Cancer's Subgroups and Their Link with Novel Immunotherapy. <i>Journal of Clinical Medicine</i> , 2020, 9, 1427.	1.0	55
125	The Prognostic Value of Deficient Mismatch Repair in Stage II-IVa Nasopharyngeal Carcinoma in the Era of IMRT. <i>Scientific Reports</i> , 2020, 10, 9690.	1.6	3
126	Global updates in the treatment of gastric cancer: a systematic review. Part 1: staging, classification and surgical treatment. <i>Updates in Surgery</i> , 2020, 72, 341-353.	0.9	23
127	Pathological Complete Response After a Single Dose of Anti-PD-1 Therapy in Combination with Chemotherapy as a First-Line Setting in an Unresectable Locally Advanced Gastric Cancer with PD-L1 Positive and Microsatellite Instability. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 1751-1756.	1.0	9
128	Chinese consensus on the diagnosis and treatment of gastric cancer with liver metastases. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592090480.	1.4	16
129	Management of early-stage gastro-esophageal cancers: expert perspectives from the Australasian Gastrointestinal Trials Group (AGITG) with invited international faculty. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 305-324.	1.1	0
130	Multicentre biomarker cohort study on the efficacy of nivolumab treatment for gastric cancer. <i>British Journal of Cancer</i> , 2020, 123, 965-972.	2.9	53
131	Impact of Tumor Localization and Molecular Subtypes on the Prognostic and Predictive Significance of p53 Expression in Gastric Cancer. <i>Cancers</i> , 2020, 12, 1689.	1.7	14
132	Multimodality treatment for localized gastric cancer: state of the art and new insights. <i>Current Opinion in Oncology</i> , 2020, 32, 347-355.	1.1	19
133	Efficacy and safety of neoadjuvant immunotherapy in patients with microsatellite instability-high gastrointestinal malignancies: A case series. <i>European Journal of Surgical Oncology</i> , 2020, 46, e33-e39.	0.5	24
134	Is Adjuvant Chemotherapy Necessary for Patients with Deficient Mismatch Repair Gastric Cancer? Autophagy Inhibition Matches the Mismatched. <i>Oncologist</i> , 2020, 25, e1021-e1030.	1.9	18

#	ARTICLE	IF	CITATIONS
135	Gastric Cancer: Where Are We Heading?. Digestive Diseases, 2020, 38, 280-285.	0.8	98
136	A novel DNA damage response signature of IDH-mutant grade II and grade III astrocytoma at transcriptional level. Journal of Cancer Research and Clinical Oncology, 2020, 146, 579-591.	1.2	4
137	Prognostic and Predictive Value of Microsatellite Instability, Inflammatory Reaction and PD-L1 in Gastric Cancer Patients Treated with Either Adjuvant 5-FU/LV or Sequential FOLFIRI Followed by Cisplatin and Docetaxel: A Translational Analysis from the ITACA-S Trial. Oncologist, 2020, 25, e460-e468.	1.9	29
138	Molecular Classification of Gastric Cancer among Alaska Native People. Cancers, 2020, 12, 198.	1.7	18
139	Microsatellite instability: a review of what the oncologist should know. Cancer Cell International, 2020, 20, 16.	1.8	269
140	New Treatment Options for Advanced Gastroesophageal Tumours: Mature for the Current Practice?. Cancers, 2020, 12, 301.	1.7	7
141	Progress in the treatment of gastric cancer in Japan over the last 50 years. Annals of Gastroenterological Surgery, 2020, 4, 21-29.	1.2	25
142	A detailed analysis of the recurrence timing and pattern after curative surgery in patients undergoing neoadjuvant therapy or upfront surgery for gastric cancer. Journal of Surgical Oncology, 2020, 122, 293-305.	0.8	10
143	Prognostic Biomarkers in Early-stage Gastric Adenocarcinoma Treated With Adjuvant Chemoradiotherapy. Cancer Genomics and Proteomics, 2020, 17, 277-290.	1.0	4
144	Next generation sequencing in gastric or gastroesophageal adenocarcinoma. Translational Gastroenterology and Hepatology, 2020, 5, 56-56.	1.5	5
145	Noninvasive imaging evaluation of tumor immune microenvironment to predict outcomes in gastric cancer. Annals of Oncology, 2020, 31, 760-768.	0.6	101
146	MSI as a predictive factor for treatment outcome of gastroesophageal adenocarcinoma. Cancer Treatment Reviews, 2020, 86, 102024.	3.4	90
147	Clinical Behavior and Treatment Response of Epstein-Barr Virus-Positive Metastatic Gastric Cancer: Implications for the Development of Future Trials. Oncologist, 2020, 25, 780-786.	1.9	14
148	Low level of microsatellite instability correlates with short disease-free survival of gastric cancer patients undergoing neoadjuvant chemotherapy. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2021, 478, 231-240.	1.4	1
149	Immunoscore is a strong predictor of survival in the prognosis of stage II/III gastric cancer patients following 5-FU-based adjuvant chemotherapy. Cancer Immunology, Immunotherapy, 2021, 70, 431-441.	2.0	10
150	The T-Cell-Inflammation Status Can Predict Outcomes of Adjuvant Chemotherapy in Patients with Gastric Cancer. Annals of Surgical Oncology, 2021, 28, 1407-1416.	0.7	4
151	Esophagogastric junction adenocarcinoma shares characteristics with gastric adenocarcinoma: Literature review and retrospective multicenter cohort study. Annals of Gastroenterological Surgery, 2021, 5, 46-59.	1.2	25
152	Locally Advanced Gastric Adenocarcinoma with Impressive Response to Hemostatic Radiation: the Possible Role of p53 Status and Eosinophilic Infiltrate. Journal of Gastrointestinal Cancer, 2021, 52, 788-791.	0.6	1

#	ARTICLE	IF	CITATIONS
153	Peri-operative Outcomes and Survival Following Palliative Gastrectomy for Gastric Cancer: a Systematic Review and Meta-analysis. <i>Journal of Gastrointestinal Cancer</i> , 2021, 52, 41-56.	0.6	13
154	Case studies highlighting the multiple facets of gastric cancer: one diagnosis, multiple approaches. , 2021, , 317-342.		0
155	Inestabilidad microsatelital y cncer gstrico. <i>Revista Colombiana De Cirugia</i> , 2021, 36, 120-131.	0.2	0
156	Approaches for the integration of big data in translational medicine: single-cell and computational methods. <i>Annals of the New York Academy of Sciences</i> , 2021, 1493, 3-28.	1.8	8
157	An Investigator-Initiated Phase 2 Study of Nivolumab Plus Low-Dose Ipilimumab as First-Line Therapy for Microsatellite Instability-High Advanced Gastric or Esophagogastric Junction Cancer (NO LIMIT,) Tj ETQq0 0 0 rgB.7/Overlock 10 Tf 50	1.7	10
158	Panel of significant risk factors predicts early stage gastric cancer and indication of poor prognostic association with pathogens and microsatellite stability. <i>Genes and Environment</i> , 2021, 43, 3.	0.9	7
159	Current treatment and recent progress in gastric cancer. <i>Ca-A Cancer Journal for Clinicians</i> , 2021, 71, 264-279.	157.7	759
161	Rare Occurrence of Microsatellite Instability in Gastrointestinal Stromal Tumors. <i>Medicina (Lithuania)</i> , 2021, 57, 174.	0.8	1
162	Management of Non-Colorectal Digestive Cancers with Microsatellite Instability. <i>Cancers</i> , 2021, 13, 651.	1.7	7
163	Neoadjuvant therapy versus surgery first for ampullary carcinoma: A propensity score-matched analysis of the NCDB. <i>Journal of Surgical Oncology</i> , 2021, 123, 1558-1567.	0.8	11
164	Detection of Microsatellite Instability: State of the Art and Future Applications in Circulating Tumour DNA (ctDNA). <i>Cancers</i> , 2021, 13, 1491.	1.7	30
165	Impact of Pancreatic Resection on Survival in Locally Advanced Resectable Gastric Cancer. <i>Cancers</i> , 2021, 13, 1289.	1.7	4
166	Targeted and immunotherapy in the era of personalised gastric cancer treatment. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2021, 50-51, 101738.	1.0	15
167	Brazilian Group of Gastrointestinal Tumours-™ consensus guidelines for the management of oesophageal cancer. <i>Ecancermedalscience</i> , 2021, 15, 1195.	0.6	1
168	The impact of recent next generation sequencing and the need for a new classification in gastric cancer. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2021, 50-51, 101730.	1.0	18
169	The Prognostic Importance of Microsatellite Instability Status in Turkish Stage II and III Gastric Cancer Patients who Received Adjuvant Chemotherapy. <i>UHOD - Uluslararası Hematoloji-Onkoloji Dergisi</i> , 2021, 31, 36-42.	0.1	0
170	Impact of microsatellite status on negative lymph node count and prognostic relevance after curative gastrectomy. <i>Journal of Surgical Oncology</i> , 2021, 123, S15-S24.	0.8	0
171	Sexual Difference Matters: Females with High Microsatellite Instability Show Increased Survival after Neoadjuvant Chemotherapy in Gastric Cancer. <i>Cancers</i> , 2021, 13, 1048.	1.7	10

#	ARTICLE	IF	CITATIONS
172	Neoadjuvant and adjuvant multimodality therapies in resectable esophagogastric adenocarcinoma. Expert Opinion on Pharmacotherapy, 2021, 22, 1429-1441.	0.9	2
173	Microsatellite instability in Gastric Cancer: Between lights and shadows. Cancer Treatment Reviews, 2021, 95, 102175.	3.4	88
174	Amplification of the human epidermal growth factor receptor 2 (HER2) gene is associated with a microsatellite stable status in Chinese gastric cancer patients. Journal of Gastrointestinal Oncology, 2021, 12, 377-387.	0.6	4
175	Multi-omics characterization and validation of MSI-related molecular features across multiple malignancies. Life Sciences, 2021, 270, 119081.	2.0	6
176	C-reactive protein adjusted for body mass index as a predictor of postoperative complications following laparoscopic gastrectomy for gastric cancer. Langenbeck's Archives of Surgery, 2021, 406, 1875-1884.	0.8	2
177	Molecular Determinants of Gastrointestinal Cancers. Advances in Oncology, 2021, 1, 311-325.	0.1	0
178	Bá»™c lá»™ Protein sá»a chá»a ghÃ©p cá»p sai AND á»Ý bá»ñnh nhÃ©n ung th»E° dá»i dÃy Äíá»u trá»« hÃ³a chá»yt bá»• trá»£ phÃ©c Ä Nghien Cuu Y Hoc, 2021, 137, 93-100.	0.0	0
180	Microsatellite instability and Epstein-Barr virus combined with PD-L1 could serve as a potential strategy for predicting the prognosis and efficacy of postoperative chemotherapy in gastric cancer. PeerJ, 2021, 9, e11481.	0.9	13
181	The Emerging Role of Liquid Biopsy in Gastric Cancer. Journal of Clinical Medicine, 2021, 10, 2108.	1.0	20
182	Her2-Positive and Microsatellite Instability Status in Gastric Cancerâ€”Clinicopathological Implications. Diagnostics, 2021, 11, 944.	1.3	15
183	Assessment of Pembrolizumab Therapy for the Treatment of Microsatellite Instabilityâ€”High Gastric or Gastroesophageal Junction Cancer Among Patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Clinical Trials. JAMA Oncology, 2021, 7, 895.	3.4	184
184	Tremellumab and Durvalumab Combination for the Non-Operative Management (NOM) of Microsatellite Instability (MSI)-High Resectable Gastric or Gastroesophageal Junction Cancer: The Multicentre, Single-Arm, Multi-Cohort, Phase II INFINITY Study. Cancers, 2021, 13, 2839.	1.7	31
185	Prediction of Sensitivity and Efficacy of Clinical Chemotherapy Using Larval Zebrafish Patient-Derived Xenografts of Gastric Cancer. Frontiers in Cell and Developmental Biology, 2021, 9, 680491.	1.8	7
186	A Machine Learning Model for Predicting a Major Response to Neoadjuvant Chemotherapy in Advanced Gastric Cancer. Frontiers in Oncology, 2021, 11, 675458.	1.3	18
187	Treatment Switch in Poor Responders with Locally Advanced Gastric Cancer After Neoadjuvant Chemotherapy. Annals of Surgical Oncology, 2021, 28, 8892-8907.	0.7	3
188	Prevalence and prognosis of microsatellite instability in oesogastric adenocarcinoma, NORDICAP 16-01. Clinics and Research in Hepatology and Gastroenterology, 2021, 45, 101691.	0.7	8
189	Cytotoxic Tâ€”lymphocyteâ€”associated protein 4 in gastric cancer: Prognosis and association with PDâ€”L1 expression. Journal of Surgical Oncology, 2021, 124, 1040-1050.	0.8	9
190	The value of restaging CT following neoadjuvant chemotherapy for resectable gastric cancer. A population-based study. World Journal of Surgical Oncology, 2021, 19, 212.	0.8	13

#	ARTICLE	IF	CITATIONS
191	Occurrence of High Microsatellite-Instability/Mismatch Repair Deficiency in Nearly 2,000 Human Adenocarcinomas of the Gastrointestinal Tract, Pancreas, and Bile Ducts: A Study From a Large German Comprehensive Cancer Center. <i>Frontiers in Oncology</i> , 2021, 11, 569475.	1.3	14
192	Gastric cancer molecular classification based on immunohistochemistry and in situ hybridization: Analysis in western patients after curative-intent surgery. <i>World Journal of Clinical Oncology</i> , 2021, 12, 688-701.	0.9	9
193	Molecular diagnostics and therapies for gastrointestinal tumors: a real-world experience. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, 148, 2137-2144.	1.2	1
194	Predictive biomarkers for 5-fluorouracil and oxaliplatin-based chemotherapy in gastric cancers via profiling of patient-derived xenografts. <i>Nature Communications</i> , 2021, 12, 4840.	5.8	27
195	Nivolumab as a representative of immune checkpoint inhibitors in late-line treatment for disseminated gastric cancer. <i>Meditinskiy Sovet</i> , 2021, , 96-107.	0.1	0
196	Tumor mutation burden is correlated with response and prognosis in microsatellite-stable (MSS) gastric cancer patients undergoing neoadjuvant chemotherapy. <i>Gastric Cancer</i> , 2021, 24, 1342-1354.	2.7	13
197	Microsatellite Instability and Effectiveness of Adjuvant Treatment in pT1N1 Gastric Cancer: A Multicohort Study. <i>Annals of Surgical Oncology</i> , 2021, 28, 8908-8915.	0.7	4
198	Immunotherapy in Gastroesophageal Cancers: Current Evidence and Ongoing Trials. <i>Current Treatment Options in Oncology</i> , 2021, 22, 100.	1.3	11
199	Tumor downstaging after neoadjuvant chemotherapy determines survival after surgery for gastric adenocarcinoma. <i>Surgery</i> , 2021, 170, 1711-1717.	1.0	7
200	MSI-WES: a simple approach for microsatellite instability testing using whole exome sequencing. <i>Future Oncology</i> , 2021, 17, 3595-3606.	1.1	4
201	Combined Therapy of Locally Advanced Oesophageal and Gastroesophageal Junction Adenocarcinomas: State of the Art and Aspects of Predictive Factors. <i>Cancers</i> , 2021, 13, 4591.	1.7	0
202	Prognostic and predictive value of mismatch repair deficiency in gastric and gastroesophageal junction adenocarcinoma patients receiving neoadjuvant or adjuvant chemotherapy. <i>Journal of Surgical Oncology</i> , 2021, 124, 1356-1364.	0.8	7
203	Prediction Model for Gastric Cancer With DNA Mismatch Repair Deficiency. <i>Anticancer Research</i> , 2021, 41, 975-982.	0.5	5
204	Digestive Tract Disease. , 2021, , 511-552.		1
205	Current state of chemotherapy and immunotherapy regimens in gastric cancer. , 2021, , 289-316.		0
206	The Clinical Significance of Microsatellite Instability in Precision Treatment. <i>Methods in Molecular Biology</i> , 2020, 2204, 33-38.	0.4	3
207	Progress and challenges in gastroesophageal cancer. <i>Current Problems in Cancer</i> , 2020, 44, 100590.	1.0	5
208	The importance of Epstein-Barr virus infection in the systemic treatment of patients with gastric cancer. <i>Seminars in Oncology</i> , 2020, 47, 127-137.	0.8	7

#	ARTICLE	IF	CITATIONS
209	Immune-related gene signature predicts overall survival of gastric cancer patients with varying microsatellite instability status. <i>Aging</i> , 2021, 13, 2418-2435.	1.4	11
210	Genomic loss of heterozygosity and survival in the REAL3 trial. <i>Oncotarget</i> , 2018, 9, 36654-36665.	0.8	13
211	Translational research and application of basic biology to clinical trial development in GI cancers. <i>Annals of Translational Medicine</i> , 2018, 6, 164-164.	0.7	6
212	Immune checkpoint inhibitors for treatment of advanced gastric or gastroesophageal junction cancer: Current evidence and future perspectives. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2020, 32, 287-302.	0.7	20
213	Current prognostic and predictive biomarkers for gastrointestinal tumors in clinical practice. <i>Pathologica</i> , 2020, 112, 248-259.	1.3	35
214	Microsatellite Status Affects Tumor Response and Survival in Patients Undergoing Neoadjuvant Chemotherapy for Clinical Stage III Gastric Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 614785.	1.3	10
215	A Multi-cohort Study of the Prognostic Significance of Microsatellite Instability or Mismatch Repair Status after Recurrence of Resectable Gastric Cancer. <i>Cancer Research and Treatment</i> , 2020, 52, 1153-1161.	1.3	9
216	Adjuvant Chemotherapy in Microsatellite Instability-High Gastric Cancer. <i>Cancer Research and Treatment</i> , 2020, 52, 1178-1187.	1.3	12
217	Precision medicine for gastrointestinal cancer: Recent progress and future perspective. <i>World Journal of Gastrointestinal Oncology</i> , 2019, 12, 1-20.	0.8	31
218	Clinical Implications of Microsatellite Instability in Early Gastric Cancer. <i>Journal of Gastric Cancer</i> , 2019, 19, 427.	0.9	15
219	Novel Biomarkers for Prediction of Response to Preoperative Systemic Therapies in Gastric Cancer. <i>Journal of Gastric Cancer</i> , 2019, 19, 375.	0.9	11
220	Target Therapy and Immunotherapy in Gastric Cancer. <i>Updates in Surgery Series</i> , 2021, , 225-233.	0.0	0
221	Tailored Treatment Strategies Based on New Molecular Classifications. <i>Updates in Surgery Series</i> , 2021, , 205-212.	0.0	0
222	The prevalence of DNA microsatellite instability in anaplastic thyroid carcinoma – systematic review and discussion of current therapeutic options. <i>Wspolczesna Onkologia</i> , 2021, 25, 213-223.	0.7	7
223	Molecular Classification of Gastric Cancer: A New Perspective for Therapy and Prognosis?. <i>Updates in Surgery Series</i> , 2022, , 13-19.	0.0	0
225	Perioperative Chemotherapy with FLOT Scheme in Resectable Gastric Adenocarcinoma: A Preliminary Correlation between TRG and Radiomics. <i>Applied Sciences (Switzerland)</i> , 2021, 11, 9211.	1.3	0
226	Mapping the genomic diaspora of gastric cancer. <i>Nature Reviews Cancer</i> , 2022, 22, 71-84.	12.8	72
227	Perioperative Treatment in Gastric Cancer – Developments in Patient Selection. <i>Journal of Cancer Therapy</i> , 2018, 09, 101-105.	0.1	1

#	ARTICLE	IF	CITATIONS
228	Perioperative chemotherapy for gastric cancer: the current state. <i>Journal of Modern Oncology</i> , 2018, 20, 56-60.	0.1	4
229	MICROSATELLITE INSTABILITY AND GASTRIC CARCINOMA. REVIEW OF THE LITERATURE. , 2019, 18, 17-24.	0.3	1
230	Gastric Adenocarcinoma. , 2020, , 199-223.		0
231	CSMD1 Mutations Are Associated with Increased Mutational Burden, Favorable Prognosis, and Anti-Tumor Immunity in Gastric Cancer. <i>Genes</i> , 2021, 12, 1715.	1.0	6
232	Detection of MSH2 Gene Methylation in Extramammary Paget's Disease by Methylation-Sensitive High-Resolution Melting Analysis. <i>Journal of Oncology</i> , 2021, 2021, 1-7.	0.6	1
233	Gastric cancer is associated with a high rate of microsatellite instability versus chronic gastritis: A retrospective study. <i>Romanian Journal of Laboratory Medicine</i> , 2020, 28, 57-65.	0.1	0
234	Prognostic Molecular Markers for Gastrointestinal Cancer. <i>Diagnostics and Therapeutic Advances in GI Malignancies</i> , 2020, , 45-53.	0.2	0
236	Adjuvant radiochemotherapy in locally advanced gastric cancer: from evidence to daily clinical practice in a single institution. <i>Ecancermedicalscience</i> , 2020, 14, 1137.	0.6	0
237	Clinical characteristics and responses to chemotherapy and immune checkpoint inhibitor treatment for microsatellite instability gastric cancer. <i>American Journal of Cancer Research</i> , 2020, 10, 4123-4133.	1.4	1
238	The Impact of Mismatch Repair Status on Prognosis of Patients With Gastric Cancer: A Multicenter Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 712760.	1.3	14
239	Characterization of Total RNA, CD44, FASN, and PTEN mRNAs from Extracellular Vesicles as Biomarkers in Gastric Cancer Patients. <i>Cancers</i> , 2021, 13, 5975.	1.7	6
240	Immunotherapy Efficacy in the Initial Lines of Treatment in Advanced Upper Gastrointestinal Malignancies: A Systematic Review of the Literature. <i>JNCI Cancer Spectrum</i> , 2021, 5, p1ab088.	1.4	2
241	Novel Biomarkers of Gastric Adenocarcinoma: Current Research and Future Perspectives. <i>Cancers</i> , 2021, 13, 5660.	1.7	16
242	Single patient classifier as a prognostic biomarker in pT1N1 gastric cancer: Results from two large Korean cohorts. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2021, 33, 583-591.	0.7	2
243	Cancer Immunotherapy with Immune Checkpoint Inhibitors-Biomarkers of Response and Toxicity; Current Limitations and Future Promise. <i>Diagnostics</i> , 2022, 12, 124.	1.3	12
244	Adjuvant radiochemotherapy in locally advanced gastric cancer: from evidence to daily clinical practice in a single institution. <i>Ecancermedicalscience</i> , 2020, 14, 1137.	0.6	0
245	Immunotherapy of Gastric Cancer: Focus on Perioperative Strategies. , 2021, , 59-73.		0
246	Optimising Multimodality Treatment of Resectable Oesophago-Gastric Adenocarcinoma. <i>Cancers</i> , 2022, 14, 586.	1.7	2

#	ARTICLE	IF	CITATIONS
247	Identification and Comprehensive Prognostic Analysis of a Novel Chemokine-Related lncRNA Signature and Immune Landscape in Gastric Cancer. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 797341.	1.8	5
248	Elevated microsatellite instability at selected tetranucleotide (<scp>EMAST</scp>) repeats in gastric cancer: a distinct microsatellite instability type with potential clinical impact?. <i>Journal of Pathology: Clinical Research</i> , 2022, 8, 233-244.	1.3	3
249	Response to neoadjuvant chemotherapy and survival in molecular subtypes of resectable gastric cancer: a post hoc analysis of the D1/D2 and CRITICS trials. <i>Gastric Cancer</i> , 2022, 25, 640-651.	2.7	10
250	Gastric adenocarcinoma peritoneal carcinomatosis: a narrative review. <i>Digestive Medicine Research</i> , 0, .	0.2	2
251	The role of DNA mismatch repair in immunotherapy of human cancer. <i>International Journal of Biological Sciences</i> , 2022, 18, 2821-2832.	2.6	20
252	Development and verification of a microsatellite instability-related risk signature for predicting survival and therapy effectiveness in gastric cancer. <i>Journal of Gastrointestinal Oncology</i> , 2022, 13, 84-101.	0.6	3
253	Short-term Outcomes of Emergent Versus Elective Gastrectomy for Gastric Adenocarcinoma: A National Surgical Quality Improvement Program Study. <i>American Surgeon</i> , 2022, , 000313482210742.	0.4	0
254	Mismatch repair deficiency, chemotherapy and survival for resectable gastric cancer: an observational study from the German staR cohort and a meta-analysis. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 1007-1017.	1.2	6
255	Adjuvant Chemotherapy in pT2N0M0 Gastric Cancer: Findings From a Retrospective Study. <i>Frontiers in Pharmacology</i> , 2022, 13, 845261.	1.6	1
256	Clinical significance of molecular subtypes of gastrointestinal tract adenocarcinoma. <i>World Journal of Gastrointestinal Oncology</i> , 2022, 14, 628-645.	0.8	6
257	A multicenter, open-label, single-arm phase I trial of neoadjuvant nivolumab monotherapy for resectable gastric cancer. <i>Gastric Cancer</i> , 2022, 25, 619-628.	2.7	18
258	Interspatial Distribution of Tumor and Immune Cells in Correlation with PD-L1 in Molecular Subtypes of Gastric Cancers. <i>Cancers</i> , 2022, 14, 1736.	1.7	4
259	Considerations and Challenges in the Management of the Older Patients with Gastric Cancer. <i>Cancers</i> , 2022, 14, 1587.	1.7	6
260	Response prediction in patients with gastric and esophagogastric adenocarcinoma under neoadjuvant chemotherapy using targeted gene expression analysis and next-generation sequencing in pre-therapeutic biopsies. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, , 1.	1.2	2
261	Immunotherapy in Gastro-Oesophageal Cancer: Current Practice and the Future of Personalised Therapy. <i>BioDrugs</i> , 2022, 36, 473-485.	2.2	5
262	Prognosis and chemosensitivity of non-colorectal alimentary tract cancers with microsatellite instability. <i>Digestive and Liver Disease</i> , 2023, 55, 123-130.	0.4	3
263	Significance of neoadjuvant downstaging in gastric adenocarcinoma. <i>Surgery</i> , 2022, 172, 593-601.	1.0	7
264	Haploinsufficiency by minute MutL homolog 1 promoter DNA methylation may represent unique phenotypes of microsatellite instability-gastric carcinogenesis. <i>PLoS ONE</i> , 2021, 16, e0260303.	1.1	0

#	ARTICLE	IF	CITATIONS
265	Gastric cancer: Russian clinical guidelines. <i>Journal of Modern Oncology</i> , 2021, 23, 541-571.	0.1	2
266	Microsatellite instability in Chinese gastric cancer and its correlation with clinical characteristics. <i>Journal of Gastrointestinal Oncology</i> , 2021, 12, 2719-2727.	0.6	0
267	Efficacy of Different Number of XELOX or SOX Chemotherapy Cycles After D2 Resection for Stage III Gastric Cancer. <i>Journal of Gastric Cancer</i> , 2022, 22, 107.	0.9	3
268	Comparison of treatment strategies and survival of early-onset gastric cancer: a population-based study. <i>Scientific Reports</i> , 2022, 12, 6288.	1.6	2
277	Automated causal inference in application to randomized controlled clinical trials. <i>Nature Machine Intelligence</i> , 2022, 4, 436-444.	8.3	8
278	Tumor Microenvironment Characterization for Assessment of Recurrence and Survival Outcome in Gastric Cancer to Predict Chemotherapy and Immunotherapy Response. <i>Frontiers in Immunology</i> , 2022, 13, 890922.	2.2	6
279	Evolution of predictive and prognostic biomarkers in the treatment of advanced gastric cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, , .	1.2	4
280	Microsatellite instability and chemosensitivity in solid tumours. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592210993.	1.4	8
281	Detection of a novel panel of 24 genes with high frequencies of mutation in gastric cancer based on next-generation sequencing. <i>World Journal of Clinical Cases</i> , 2022, 10, 4761-4775.	0.3	2
282	Immunotherapy in upper gastrointestinal malignancies. <i>Onkologie (Czech Republic)</i> , 2022, 16, 123-126.	0.0	0
283	Complete Response of High Microsatellite Instability Gastric Cancer and Synchronous Microsatellite Stability Rectal Cancer. <i>Cureus</i> , 2022, , .	0.2	0
284	Conversion surgery for microsatellite instability-high gastric cancer with a complete pathological response to pembrolizumab: a case report. <i>World Journal of Surgical Oncology</i> , 2022, 20, .	0.8	3
285	The LEGACy study: a European and Latin American consortium to identify risk factors and molecular phenotypes in gastric cancer to improve prevention strategies and personalized clinical decision making globally. <i>BMC Cancer</i> , 2022, 22, .	1.1	2
286	Survival of Locally Advanced MSI-high Gastric Cancer Patients Treated With Perioperative Chemotherapy. <i>Annals of Surgery</i> , 2023, 277, 798-805.	2.1	8
287	Impact of mismatch repair deficiency on tumour regression grade after neoadjuvant chemotherapy in localized gastroesophageal adenocarcinoma. <i>Digestive and Liver Disease</i> , 2023, 55, 276-282.	0.4	1
288	Stem Cell Theory of Cancer: Implications for Translational Research from Bedside to Bench. <i>Cancers</i> , 2022, 14, 3345.	1.7	4
289	Current molecular biomarkers evaluation in gastric/gastroesophageal junction adenocarcinoma: pathologist does matter. <i>Updates in Surgery</i> , 2023, 75, 291-303.	0.9	5
291	Understanding the association between clinical staging accuracy, treatment response, and survival among gastric cancer patients through Bayesian analysis. <i>Journal of Surgical Oncology</i> , 0, , .	0.8	0

#	ARTICLE	IF	CITATIONS
292	Esophagogastric Cancers: Integrating Immunotherapy Therapy Into Current Practice. <i>Journal of Clinical Oncology</i> , 2022, 40, 2751-2762.	0.8	27
293	Microsatellite instability and sex differences in resectable gastric cancer – A pooled analysis of three European cohorts. <i>European Journal of Cancer</i> , 2022, 173, 95-104.	1.3	9
294	Immunotherapy in MSI/dMMR tumors in the perioperative setting: The IMHOTEP trial. <i>Digestive and Liver Disease</i> , 2022, 54, 1335-1341.	0.4	12
295	Neoadjuvant treatment in gastric cancer. <i>Memo - Magazine of European Medical Oncology</i> , 0, , .	0.3	1
296	Factors affecting prognosis in signet ring cell gastric cancers with expanded lymph node dissection; high volume centre experience. <i>International Surgery Journal</i> , 2022, 9, 1406.	0.0	0
298	Neoadjuvant Nivolumab Plus Ipilimumab and Adjuvant Nivolumab in Localized Deficient Mismatch Repair/Microsatellite Instability–High Gastric or Esophagogastric Junction Adenocarcinoma: The GERCOR NEONIPIGA Phase II Study. <i>Journal of Clinical Oncology</i> , 2023, 41, 255-265.	0.8	98
300	Neoadjuvant and Adjuvant Therapy Approaches to Gastric Cancer. <i>Current Treatment Options in Oncology</i> , 2022, 23, 1247-1268.	1.3	19
301	Microsatellite Instability: From the Implementation of the Detection to a Prognostic and Predictive Role in Cancers. <i>International Journal of Molecular Sciences</i> , 2022, 23, 8726.	1.8	18
302	Common strategies for effective immunotherapy of gastroesophageal cancers using immune checkpoint inhibitors. <i>Pathology Research and Practice</i> , 2022, 238, 154110.	1.0	1
303	Research Progress of MSI Gastric Cancer Subtypes. <i>Advances in Clinical Medicine</i> , 2022, 12, 6719-6723.	0.0	0
304	Optimizing the Choice for Adjuvant Chemotherapy in Gastric Cancer. <i>Cancers</i> , 2022, 14, 4670.	1.7	4
305	Proteomic characterization of gastric cancer response to chemotherapy and targeted therapy reveals potential therapeutic strategies. <i>Nature Communications</i> , 2022, 13, .	5.8	18
306	The order of surgery and chemotherapy matters: Multimodality therapy and stage–specific differences in survival in gastric cancer. <i>Journal of Surgical Oncology</i> , 2023, 127, 56-65.	0.8	3
307	Comparison of response evaluation criteria in solid tumors and tumor regression grade in evaluating the effect of preoperative systemic therapy of gastric cancer. <i>BMC Cancer</i> , 2022, 22, .	1.1	3
308	Molecular Pathology of Gastric Cancer. <i>Journal of Gastric Cancer</i> , 2022, 22, 264.	0.9	6
309	Advances in sex disparities for cancer immunotherapy: unveiling the dilemma of Yin and Yang. <i>Biology of Sex Differences</i> , 2022, 13, .	1.8	9
310	Predictive biomarkers in gastric cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 467-481.	1.2	27
311	A multi-institutional study to evaluate the feasibility of next-generation sequencing and genomic analysis using formalin-fixed, paraffin-embedded biopsies of gastric cancer. <i>Gastric Cancer</i> , 0, , .	2.7	2

#	ARTICLE	IF	CITATIONS
313	Immune checkpoint inhibitors in resectable gastroesophageal cancers - a review. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592211396.	1.4	0
314	EBV and MSI Status in Gastric Cancer: Does It Matter?. <i>Cancers</i> , 2023, 15, 74.	1.7	6
315	Models for Predicting Response to Immunotherapy and Prognosis in Patients with Gastric Cancer: DNA Damage Response Genes. <i>BioMed Research International</i> , 2022, 2022, 1-21.	0.9	3
316	Dual immune checkpoint blockade in gastroesophageal tumors: never say never. <i>Memo - Magazine of European Medical Oncology</i> , 0, , .	0.3	1
317	Is there still a place for radiotherapy in gastric cancer?. <i>Current Opinion in Pharmacology</i> , 2023, 68, 102325.	1.7	2
318	The evolution of treatment for resectable gastric cancer. , 2023, 2, 100008.		0
319	Gastric adenocarcinoma with high level microsatellite instability: A case report. <i>Molecular and Clinical Oncology</i> , 2023, 18, .	0.4	0
320	Clinical significance of neoadjuvant chemotherapy for locally advanced colorectal cancer patients with deficient mismatch repair: possibly residual value in the era of immunotherapy. <i>Therapeutic Advances in Gastroenterology</i> , 2023, 16, 175628482211503.	1.4	0
321	Neoadjuvant Chemotherapy in Asian Patients With Locally Advanced Gastric Cancer. <i>Journal of Gastric Cancer</i> , 2023, 23, 182.	0.9	1
322	Correlation between mismatch repair and survival of patients with gastric cancer after 5-FU-based adjuvant chemotherapy. <i>Journal of Gastroenterology</i> , 2023, 58, 622-632.	2.3	1
323	Updated Immunotherapy for Gastric Cancer. <i>Journal of Clinical Medicine</i> , 2023, 12, 2636.	1.0	6
324	Response Evaluation after Neoadjuvant Chemotherapy for Resectable Gastric Cancer. <i>Cancers</i> , 2023, 15, 2318.	1.7	2
325	Gastric cancer with microsatellite instability displays increased thymidylate synthase expression. <i>Journal of Surgical Oncology</i> , 2022, 126, 116-124.	0.8	1
326	Mismatch Repair Status Characterization as an Immune-Related Biomarker in Oncology. , 2023, , 1-21.		0
327	Increased CD4/CD8 Lymphocyte ratio predicts favourable neoadjuvant treatment response in gastric cancer: A prospective pilot study. <i>World Journal of Gastrointestinal Oncology</i> , 0, 15, 303-317.	0.8	4
328	Microsatellite instability and DNA mismatch repair deficiency detection in tumors of various sites. <i>Arkhiv Patologii</i> , 2023, 85, 36.	0.0	0
329	Relation between mismatch repair status, chemoresponse, survival and anatomic location in gastroesophageal adenocarcinoma. <i>Canadian Journal of Surgery</i> , 2023, 66, E79-E87.	0.5	1
330	Pattern of recurrence and overall survival in esophagogastric cancer after perioperative FLOT and clinical outcomes in MSI-H population: the PROSECCO Study. <i>Journal of Cancer Research and Clinical Oncology</i> , 0, , .	1.2	4

#	ARTICLE	IF	CITATIONS
331	Assessing Epstein-Barr virus in gastric cancer: clinicopathological features and prognostic implications. <i>Infectious Agents and Cancer</i> , 2023, 18, .	1.2	1
332	ASAP1 activates the IQGAP1/CDC42 pathway to promote tumor progression and chemotherapy resistance in gastric cancer. <i>Cell Death and Disease</i> , 2023, 14, .	2.7	3
335	Perioperative Tailored Treatments for Gastric Cancer: Times Are Changing. <i>International Journal of Molecular Sciences</i> , 2023, 24, 4877.	1.8	5
336	A noninvasive nomogram model based on CT features to predict DNA mismatch repair deficiency in gastric cancer. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	0
338	Effect of multimodal chemotherapy on survival of gastric cancer with liver metastasis – a population based analysis. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	1
339	Impact of Programmed Death-Ligand 1 Expression on Mismatch Repair Deficiency and Epstein-Barr Virus Status on Survival Outcomes in Patients with Stage II/III Gastric Cancer After Surgery. <i>Annals of Surgical Oncology</i> , 2023, 30, 5227-5236.	0.7	2
340	Current trends in perioperative treatment of resectable gastric cancer. <i>World Journal of Gastrointestinal Surgery</i> , 0, 15, 323-337.	0.8	0
341	Controversies and management of deficient mismatch repair gastrointestinal cancers in the neoadjuvant setting. <i>Therapeutic Advances in Medical Oncology</i> , 2023, 15, 175883592311625.	1.4	0
342	Landscape of KRAS, BRAF, and PIK3CA Mutations and Clinical Features of EBV-Associated and Microsatellite Unstable Gastric Cancer. <i>Molecular Biology</i> , 2023, 57, 61-73.	0.4	1
343	Microsatellite instability and sex-specific differences of survival in gastric cancer after neoadjuvant chemotherapy without and with taxane: An observational study in real world patients. <i>Journal of Cancer Research and Clinical Oncology</i> , 0, , .	1.2	0
344	Gastric cancer with impaired DNA unpaired nucleotide repair system. <i>Arkhiv Patologii</i> , 2023, 85, 44.	0.0	0
345	Identification of mitochondrial respiratory chain signature for predicting prognosis and immunotherapy response in stomach adenocarcinoma. <i>Cancer Cell International</i> , 2023, 23, .	1.8	0
346	Role of microsatellite instability and HER2 positivity in locally advanced esophago-gastric cancer patients treated with peri-operative chemotherapy. <i>Clinical and Translational Oncology</i> , 0, , .	1.2	0
352	Early stage gastric adenocarcinoma: clinical and molecular landscapes. <i>Nature Reviews Clinical Oncology</i> , 2023, 20, 453-469.	12.5	7
362	Perioperative immune checkpoint inhibitor therapy for gastric and gastroesophageal junction cancers: a review of current approaches and future perspectives. <i>International Journal of Clinical Oncology</i> , 0, , .	1.0	0
375	Immunoneoadjuvant therapy with immune checkpoint inhibitors of gastric cancer: an emerging exemplification. <i>Investigational New Drugs</i> , 2024, 42, 1-13.	1.2	0
379	Translating Molecular Subtypes into Clinical Practice: Precision Medicine in Gastric Cancer. , 0, , .		0
383	Management of Microsatellite Instability High (MSI-H) Gastroesophageal Adenocarcinoma. <i>Journal of Gastrointestinal Cancer</i> , 0, , .	0.6	0

#	ARTICLE	IF	CITATIONS
386	Molecular biomarkers in gastric cancer. , 2024, , 105-119.		0
391	Special Type of Surgical Resection for Gastric Cancer. , 2023, , 41-113.		0
392	The Comprehensive Treatment for Gastric Cancer. , 2023, , 141-176.		0